A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis

A Multicenter, Single-arm, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetics of CM310 in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05579925

Enrollment

Registered

2022-10-14

Start date

2022-10-07

Completion date

2023-07-28

Last updated

2024-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Brief summary

This is a multi-center, single arm, open-label study to evaluate safety and primary efficacy in children patients with moderate-to severe atopic dermatis.

Interventions

BIOLOGICALCM310

CM310 600 mg + 300 mg, subcutaneous injection

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

12 Years to 18 Years

Healthy volunteers

Inclusion criteria

* 12 years ≤ age ≤ 18 years * With atopic dermatis * Voluntarily sign the informed consent form

Exclusion criteria

* Weight \< 30 kg * Major surgery planed during the study

Design outcomes

Primary

Measure	Time frame	Description
Adverse events	at week 14	Incidence of adverse events.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026